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1Background—The P wave on an ECG is a measure of atrial electric function, and its characteristics may serve as predictors 
for atrial arrhythmias. Increased mean P-wave duration and P-wave terminal force traditionally have been used as markers 
for left atrial enlargement, and both have been associated with increased risk of atrial fibrillation. Here, we explore the 
genetic basis of P-wave morphology through meta-analysis of genome-wide association study results for P-wave duration 
and P-wave terminal force from 12 cohort studies.
Methods and Results—We included 44 456 individuals, of which 6778 (16%) were of African ancestry. Genotyping, 
imputation, and genome-wide association study were performed at each study site. Summary-level results were meta-
analyzed centrally using inverse-variance weighting. In meta-analyses of P-wave duration, we identified 6 significant 
(P<5×10−8) novel loci and replicated a prior association with SCN10A. We identified 3 loci at SCN5A, TBX5, and CAV1/
CAV2 that were jointly associated with the PR interval, PR segment, and P-wave duration. We identified 6 novel loci 
in meta-analysis of P-wave terminal force. Four of the identified genetic loci were significantly associated with gene 
expression in 329 left atrial samples. Finally, we observed that some of the loci associated with the P wave were linked 
to overall atrial conduction, whereas others identified distinct phases of atrial conduction.
Conclusions—We have identified 6 novel genetic loci associated with P-wave duration and 6 novel loci associated with P-wave 
terminal force. Future studies of these loci may aid in identifying new targets for drugs that may modify atrial conduction 
or treat atrial arrhythmias.  (Circ Cardiovasc Genet. 2017;10:e. DOI: 10.1161/CIRCGENETICS.116.001667.)
Key Words: arrhythmia ◼ atrial function ◼ electrocardiography ◼ genetic variation  
◼ genome-wide association study
© 2017 American Heart Association, Inc.
Circ Cardiovasc Genet is available at http://circgenetics.ahajournals.org DOI: 10.1161/CIRCGENETICS.116.001667
Received November 10, 2016; accepted May 15, 2017.
Guest Editor for this article was Christopher Semsarian, MBBS, PhD, MPH.
*Drs Christophersen, Magnani, and Yin contributed equally to this work.
The Data Supplement is available at http://circgenetics.ahajournals.org/lookup/suppl/doi:10.1161/CIRCGENETICS.116.001667/-/DC1.
Correspondence to Jared W. Magnani, MD, MSc, Department of Medicine, Division of Cardiology, UPMC Heart and Vascular Institute, University of 
Pittsburgh, Pittsburgh, Pennsylvania, USA. E-mail magnanijw@upmc.edu or Patrick T. Ellinor, MD, PhD, Broad Institute of Harvard and MIT, 75 Ames 
St, Cambridge, MA 02124. E-mail ellinor@mgh.harvard.edu
Fifteen Genetic Loci Associated 
With the Electrocardiographic P Wave
Ingrid E. Christophersen, MD, PhD*; Jared W. Magnani, MD, MSc*; Xiaoyan Yin, PhD*;  
John Barnard, PhD; Lu-Chen Weng, PhD; Dan E. Arking, PhD; Maartje N. Niemeijer, MD;  
Steven A. Lubitz, MD, MPH; Christy L. Avery, PhD; Qing Duan, PhD; Stephan B. Felix, MD;  
Joshua C. Bis, PhD; Kathleen F. Kerr, PhD; Aaron Isaacs, PhD;  
Martina Müller-Nurasyid, PhD; Christian Müller, MSc; Kari E. North, PhD;  
Alex P. Reiner, MD, MSc; Lesley F. Tinker, PhD, RD; Jan A. Kors, PhD;  
Alexander Teumer, PhD; Astrid Petersmann, MD; Moritz F. Sinner, MD, MPH;  
Petra Buzkova, PhD; Jonathan D. Smith, PhD; David R. Van Wagoner, PhD;  
Uwe Völker, PhD; Melanie Waldenberger, PhD; Annette Peters, PhD; Thomas Meitinger, MD;  
Marian C. Limacher, MD; Kirk C. Wilhelmsen, MD, PhD; Bruce M. Psaty, MD, PhD;  
Albert Hofman, MD, PhD; Andre Uitterlinden, PhD; Bouwe P. Krijthe, MD, PhD;  
Zhu-Ming Zhang, MD, MPH; Renate B. Schnabel, MD, MSc; Stefan Kääb, MD;  
Cornelia van Duijn, PhD; Jerome I. Rotter, MD; Nona Sotoodehnia, MD, PhD;  
Marcus Dörr, MD; Yun Li, PhD; Mina K. Chung, MD; Elsayed Z. Soliman, MD, MSc, MS;  
Alvaro Alonso, MD, PhD; Eric A. Whitsel, MD, MPH; Bruno H. Stricker, MMed, PhD;  
Emelia J. Benjamin, MD, ScM; Susan R. Heckbert, MD, PhD; Patrick T. Ellinor, MD, PhD
Original Article
The electrocardiographic P wave is a measure of electric activation of the atria and was first described by Bayliss 
and Starling over 120 years ago.1 P-wave indices (PWI) 
describe atrial electric function and are quantified as measures 
of duration and voltage from the surface ECG. The clinical 
utility of PWI has been demonstrated by their relation to atrial 
electrophysiology using invasive intracardiac studies2,3 and by 
their assessment as risk factors for atrial fibrillation (AF).4–7 
D
ow
nloaded from
 http://ahajournals.org by on August 17, 2018
2  Christophersen et al  Genetic Basis of the P Wave 
P-wave terminal force—derived from the product of the dura-
tion of the negative phase of the P wave in lead V1 and its 
terminal depth (Figure 1)—has been used as an ECG marker 
for the presence of left atrial enlargement.8 In addition to ter-
minal force, P-wave duration has been used widely because of 
its accessibility from the ECG. Elucidation of the associations 
of genetic variants related to PWI may improve our under-
standing of the biology underlying atrial conduction and fur-
ther inform the genetic determinants of risk of arrhythmias, 
including AF.
See Editorial by Bezzina  
See Clinical Perspective
We sought to enhance our understanding of atrial elec-
tric function by conducting large genome-wide association 
studies (GWAS) of PWI in individuals of European and 
African ancestry. Prior GWAS have distinguished genetic loci 
uniquely associated with P-wave duration from those associ-
ated with the PR interval and the PR segment.9,10 The larg-
est study evaluating common variants associated with P-wave 
maximal duration, to date, included 16 468 individuals of 
European ancestry and identified 3 significant genetic loci.10 
There have been no reports on common genetic variants asso-
ciated with P-wave terminal force.
In the present investigation, we examined the genome-wide 
associations of maximum P-wave duration and P-wave terminal 
force in 12 cohorts, including >44 000 individuals of European 
and African American ancestry. We hypothesized that the PWI 
examined have novel genetic associations, distinct from those 
previously identified as associated with the PR interval.
Materials and Methods
Study Cohorts
Participants of European or African ancestry from 12 studies contrib-
uted to the present analyses (Table I in the Data Supplement): ARIC 
Study (Atherosclerosis Risk in Communities), CHS (Cardiovascular 
Health Study), ERF Study (Erasmus Rucphen Family), FHS 
(Framingham Heart Study), KORA (Cooperative Health Research in 
the Augsburg Region), GHS I (Gutenberg Health Study I), MESA 
(Multi-Ethnic Study of Atherosclerosis), RS I-III (Rotterdam 
Studies I, II, and III), SHIP (Study of Health in Pomerania), and 3 
distinct studies affiliated with the Women’s Health Initiative (WHI) 
clinical trials: GARNET (Genome-wide Association Research 
Network), MOPMAP (Modification of Particulate Matter–Mediated 
Arrhythmogenesis in Populations), and SHARe (SNP Health 
Association Resource Project). The study was limited to participants 
with available DNA and consent for genetics research. We excluded 
individuals in whom we could not determine PWI and individuals 
with a history of AF, an implanted pacemaker or ICD, WPW syn-
drome, and complete heart block or who received medication altering 
atrioventricular nodal conduction (β-blockers, dihydropyridine cal-
cium channel blockers, type I and III antiarrhythmic medication, and 
digoxin). Individuals with mitral valve disease were not excluded. All 
participants had given their written informed consent to participation, 
and all studies were approved by their respective institutional review 
boards or equivalent ethical committees.
PWI Measurement
Participants in all cohorts underwent a standardized, digital 12-lead 
ECG at rest in the supine position as a component of the cohort ex-
amination. All PWI were quantified using contemporary software al-
gorithms from digitized tracings. Electrocardiograms from the ARIC, 
CHS, and MESA and data from the 3 WHI clinical trials substudies were 
automatically processed at the Epidemiological Cardiology Research 
Center of Wake Forest University School of Medicine (Winston Salem, 
NC) using General Electric (GE) 12-SL software (GE, Milwaukee, 
WI) running under GE MUSE and Magellan Research Work Station. 
ECGs in FHS were read independently at FHS and analyzed using GE 
12-SL software. PWI calculated using GE 12-SL software have pre-
viously been reported as having a repeatability of 100%.4 In GHS I, 
ECGs were recorded using the Welch Allyn CardioPerfect electrocar-
diograph (Skaneateles Falls, NY), and PWI were calculated using the 
GE Healthcare software CASE, CardioSoft, version 6 (Palatine, IL). In 
ERF and RSI-III, electrocardiograms were recorded using the ACTA 
Gnosis IV ECG recorder (Esaote Biomedica, Florence, Italy), and in 
SHIP, electrocardiograms were recorded using the Personal 120LD 
(Esaote, Genova, Italy). In ERF, RSI-III, and SHIP, electrocardiograms 
were analyzed with the Modular ECG Analysis System.11 KORA used 
the AMEDTEC ECGpro system (AMEDTEC Medizintechnik Aue 
GmbH, Aue, Germany) and analyzed tracings using the Hannover 
ECG system (Corscience GmbH&Co. KG, Erlangen, Germany).
PWI were selected for their availability across cohorts. P-wave 
duration in each lead was calculated by summing the durations of 
the positive and negative phase of the P wave in each lead. The maxi-
mum P-wave duration was selected as the highest value among the 
12 leads. P-wave terminal force, specific to right precordial lead V1, 
was calculated as the product of the duration and voltage of the nega-
tive deflection of the P wave in lead V1. Distributions of the PWI 
by cohort are presented in Table II in the Data Supplement. P-wave 
terminal force was not available in KORA and GHS.
Genotyping
Details on genotyping methods, quality control, imputation, and soft-
ware are provided in detail in Table III in the Data Supplement. All 
cohorts used genome-wide arrays for genotyping. Genotyping was 
performed independently in each cohort using the following arrays: 
Affymetrix 6.0 genome-wide array (ARIC, KORA, GHS, MESA, 
SHIP, and WHI SHARe), Illumina 370 (CHS), Affymetrix 500K+50K 
(FHS), Illumina Infinium (RSI-III), Illumina Quad (WHI GARNET), 
and Affymetrix Titan (MOPMAP). Samples with call rates <95% 
(ARIC, GHS, MESA, WHI MOPMAP, and WHI SHARe), <97% 
(CHS, FHS), or <98% (KORA, Rotterdam, ERF, and GARNET) at 
genotyped markers were excluded.
Expression Quantitative Trait Loci Analyses
A complete description is enclosed in Methods in the Data 
Supplement. In brief, expression Quantitative Trait Loci (eQTL) 
analyses were performed from human left atrial tissue samples and 
from the Genotype-Tissue Expression (GTEx) database.
Figure 1. Calculation of P wave terminal force. ECG with the 
P wave highlighted in green and calculation of P wave terminal 
force depicted in lead V1.
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Estimation of the Variance Explained by the 
Significant Genetic Variants
Results from the meta-analyses were used to estimate the percentage 
of the variance that can be explained by the most significant single 
nucleotide polymorphism (SNP) at each genetic locus as described 
by Hibar et al.12 We calculated estimated variance explained for SNPs 
identified in both separate and combined ancestry analyses and ad-
justed for age, sex, RR interval, and the maximum number of princi-
pal components adjusted for in any of the ancestry-matched GWAS.
Evaluation of the Genetic Associations Between 
P-Wave Duration and P-Wave Terminal Force
We performed a summary-level analysis to test the association be-
tween the genetic variants associated with P-wave duration and the 
measured P-wave terminal force and vice versa in the European an-
cestry group. To define independent signals, we performed linkage 
disequilibrium (LD) clumping by selecting SNPs with P<1×10−5 and 
assigning all SNPs within 250 kb in each direction in moderate LD 
(r2>0.5) and P<0.05 to the same clump. LD clumping was iterated un-
til all SNPs with P<1×10−5 had been clumped, using PLINK v.1.9.13 
To assess whether the selected LD threshold was sufficient to identify 
independent variants, we also performed LD clumping using lower 
thresholds (r2>0.1 and r2>0.05). LD information was obtained from the 
Framingham Heart Study. Genetic risk scores (GRS) were then created 
for both ECG traits, including only SNPs significantly associated with 
the trait and that were not in LD with any other significant SNPs. The 
scores were used to evaluate the association between the genetically 
determined P-wave duration and measured P-wave terminal force and 
between the genetically determined P-wave terminal force and mea-
sured P-wave duration, using the R-package gtx.14 The association re-
sults were then used to estimate the fraction of the total variance of each 
trait that could be explained by the GRS of the other trait.
Statistical Analysis
Each cohort conducted an independent association analysis relating 
genotype to P-wave duration and P-wave terminal force. Cohorts with 
participants of African ancestry performed separate analyses by race. 
Adjustment for principal components was performed in individual 
studies if appropriate. Cohorts used linear regression models that 
adjusted for participant age, sex, RR interval, and cohort or site in 
a primary analysis and further adjusted for hypertension (defined as 
systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 
mm Hg, or treatment with an antihypertensive) and body mass index 
(weight [kg]/height [m]2) in a secondary analysis.
Genetic variants were given a marker identifier (ID) consisting of 
chromosome number and chromosomal position before meta-anal-
ysis to avoid inconsistencies in reference SNP ID numbers (rsIDs) 
from the Single Nucleotide Polymorphism database (dbSNP) across 
different builds. Cohort-specific summary statistics were pooled for 
inverse-variance weighted fixed-effect meta-analyses, which were 
performed separately for maximum P-wave duration and P-wave ter-
minal force. Both ancestry-specific and combined ancestry analyses 
were performed for both traits. Variants that were not present in at 
least 2 studies were excluded. Associations with 2-sided P<5×10−8 
were considered genome-wide significant.
Results
The study sample for maximum P-wave duration included 
37 678 individuals of European ancestry and 6778 of African 
ancestry. Because KORA and GHS did not contribute to anal-
yses of the P-wave terminal force, the total number of individ-
uals of European ancestry for that meta-analysis was 33 955. 
Descriptive characteristics of the study participants are pro-
vided in Table II in the Data Supplement. The 3 WHI clini-
cal trial cohorts included only women, while the remaining 
cohorts included both sexes. Mean age within study ranged 
from 46±16 to 72±5 years. Mean P-wave duration was highly 
consistent across cohorts. In contrast, P-wave terminal force 
had a wider range with proportionately larger standard devia-
tion. Details regarding study design, genotyping, GWAS, and 
imputation are listed in Table III in the Data Supplement.
P-Wave Duration
In the primary analyses, we identified 9 loci associated with 
P-wave duration, 5 of which have not been associated with 
P-wave duration previously. The most significant variant from 
each locus is listed in Tables IV and Table V in the Data Sup-
plement. Table VI in the Data Supplement displays a com-
parison of the genome-wide significant loci across P-wave 
duration and P-wave terminal force analyses. Figure 2 depicts 
the Manhattan plots for the P-wave duration analysis, strati-
fied by ancestry. Figure IA in the Data Supplement shows 
the Manhattan plot for pooled ancestries, and Figure II in the 
Data Supplement shows the regional plots for all genetic loci 
associated with P-wave duration in this study. Table VII in the 
Data Supplement summarizes the relationship between sig-
nificant genetic loci in the present GWAS of P-wave duration 
and previous PWI GWAS.
Genetic Loci Unique to P-Wave Duration
We identified an association between P-wave duration and a 
variant on chromosome 5 (rs4276421) that resides ≈100 kb 
upstream of HCN1. On chromosome 7, we identified a locus 
comprising CAV1 and CAV2, with the most significant vari-
ant located intronic to CAV1. More than 40 variants at this 
locus had significant or near significant eQTLs for CAV1/
CAV2 in European American left atrial samples (Table VIII 
in the Data Supplement). The most significant variant in the 
combined ancestry analysis (rs3801995) was in moderate LD 
(Utah residents with Northern and Western European ances-
try from the Centre d'Etude du Polymorphisme Humain col-
lection [CEU] r2=0.56), with the most significant variants in 
previous GWAS of PR interval,10,15–17 which are in perfect LD 
(rs3807989 and rs11773845; CEU r2=1) with each other. The 
most significant variant in Europeans (rs13242816) was not 
in LD (CEU r2=0.11) with previously identified variants at 
this locus. A third locus was identified on chromosome 2, and 
the top hit (rs11689011) was intronic to the gene EPAS1. On 
chromosome 1, we identified a locus (most significant SNP 
rs562408) surrounding the gene SSBP3. The lead SNP and 5 
other variants were significant eQTLs for SSBP3 in European 
American left atrial samples (Table VIII in the Data Supple-
ment), and the lead SNP in Europeans was the strongest cis 
eQTL for this gene; similar results were found in the GTEx 
database (Table IX in the Data Supplement). Another locus 
was located on chromosome 4 with rs2285703 intronic to the 
gene CAMK2D.
Last, in the meta-analysis of European and African-
American ancestries combined, we identified an additional 
genetic locus associated with P-wave duration on chromo-
some 3. The top variant, rs1467026, was located upstream of 
CAND2 and was in moderate LD (CEU r2=0.67) with a variant 
associated with AF by Sinner et al18 in 2014. Rs1467026 has 
been shown to be a significant eQTL for CAND2 (P=7.5×10–
27) in skeletal muscle in the GTEx database (Table IX in the 
Data Supplement), though this was not found to be a signifi-
cant eQTL in left atrial tissues.
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Genetic Loci Previously Associated With 
Electrocardiographic Traits
We identified an association between P-wave duration and the 
SCN5A region in both Europeans and African Americans. The 
most significant European variant (rs41312411) at the SCN5A 
locus was in strong LD with the most significant variant 
(rs11708996; CEU r2=0.94) from the first PR interval GWAS 
by Pfeufer et al15 and in moderate LD with a variant associated 
with both PR segment10 and PR interval19 (rs6599222; CEU 
r2=0.55). In African Americans, we replicated the association 
between SNP rs3922844 and the PR interval observed in 2 
previous GWAS in African Americans19,20; this variant also 
has been associated with the PR segment in Europeans.10
In individuals of European ancestry, we identified an addi-
tional association signal in the adjacent SCN10A gene. The 
most significant variant at the SCN10A locus (rs6790396) was 
in strong LD with the following previously identified variants: 
(1) rs6800541 (CEU r2=1), which was previously associated 
with PR interval15; (2) rs6795970 (CEU r2=0.97), which was 
associated with both PR interval and P-wave duration in an 
Indian Asian population21 and PR interval in Europeans16; and 
(3) rs6801957 (CEU r2=0.97), which was associated with PR 
interval,20,22 PR segment,10 and P-wave duration.10 There also 
was strong (CEU r2=0.87) and moderate (Yoruba in Ibadan, 
Nigeria [YRI] r2=0.51) LD between our lead SCN10A variant 
and a variant associated with PR interval in African Americans 
(rs6798015).
In both Europeans and African Americans, we identified 
a locus with the most significant variant located intronic 
to the gene TBX5. The lead variants in all ancestry analy-
ses were significant eQTLs for TBX5 in both European 
American and African American left atrial samples (Table 
VIII in the Data Supplement). The most significant SNP in 
the African American ancestry group (rs1895582) was also 
an eQTL for TBX5 in left ventricular tissue in GTEx (Table 
IX in the Data Supplement). The same SNP, rs1895582, 
was in strong LD (YRI r2=0.81) with a variant previously 
associated with PR interval in African Americans. The most 
significant variant (rs148020424) in Europeans was sur-
rounded by an ≈300 kb LD block, bordered by 2 recombi-
nation hot spots. There were no LD data available between 
rs148020424 and previously associated SNPs at this locus. 
However, the most significant variant in our combined 
ancestry analysis (rs7312625) was previously associated 
with PR interval in African Americans. Rs7312625 was in 
strong LD (YRI r2=0.81) with the most significant variant 
in African Americans in our study and in moderate LD with 
rs1895585 (YRI r2=0.78), the most significant variant in 
the TBX5 region from a previous GWAS on PR interval in 
African Americans.20 SNP rs7312625 was also in moderate 
LD with rs3825214 (CEU r2=0.76), an intronic variant in 
TBX5 previously associated with heart rate in Europeans.16
We identified an association between P-wave dura-
tion and variant rs452036 on chromosome 14 in a region 
Figure 2. Manhattan plot of meta-analysis results for genome-wide association of maximum P wave duration for European and African 
American ancestry. A, European ancestry meta-analysis results. B, African American ancestry meta-analysis results. The dashed horizon-
tal lines represent the genome-wide significance threshold. Genetic loci that reached genome-wide significance are highlighted in red.
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encompassing MYH6 and MYH7, and the same variant was 
also significantly associated with P-wave terminal force in our 
study. Rs452036 was the most significant variant in a GWAS 
for heart rate by Eijgelsheim et al23 in 2010 and was in strong 
LD with rs365990 (CEU r2=0.96, YRI r2=1), which has been 
associated with heart rate in studies of both European and 
African American ancestry.16,23–25 Rs452036 was not in LD 
(CEU r2=0.16) with the heart rate–associated SNP rs223116, 
which is intronic to MYH7 and, thus, most likely represents an 
independent locus for heart rate.23
P-Wave Terminal Force
In the primary analysis, we identified 6 loci associated with 
P-wave terminal force. The most significantly associated 
variants are listed in Tables X and XI in the Data Supple-
ment; Figure 3 depicts the Manhattan plots, stratified by 
ancestry. The Manhattan plot for the pooled analysis of 
Europeans and African Americans is shown in Figure IB 
in the Data Supplement, and regional plots for all genetic 
loci significantly associated with P-wave terminal force are 
shown in Figure III in the Data Supplement. Table XII in 
the Data Supplement summarizes the shared associations 
of genetic loci between the present P-wave terminal force 
analysis and previous GWAS of PWI.
Genetic Loci Unique to the P Wave Terminal Force
In the European study populations, the locus with the 
strongest association was identified on chromosome 1 
(rs12090194), intronic to KCND3. Rs12090194 was in weak 
LD (CEU r2=0.2) with rs2798334, which has been associ-
ated with P-wave duration by Verweij et al10; thus, this locus 
seems to be specific to P-wave terminal force. A second locus 
was identified on chromosome 19, with the most signifi-
cant variant (rs4435363) intronic to the gene PPP5D1 and 
downstream of the gene CALM3. On chromosome 15q25, 
the most significant variant was an indel (rs201517563), 
intronic to ALPK3. This variant was not present in the 1000 
Genomes database reference, and so there were no available 
LD data. However, LD data were available for the second 
most significant variant at this locus (rs11073730), which 
was located between ALPK3 and ZNF592. The 15q25 locus 
spanned several other genes, including NMB, for which there 
were multiple significant eQTLs in European American left 
atrial samples (Table XIII in the Data Supplement), and 
rs11073730 was also a significant eQTL for several genes 
in various tissues in GTEx, including ALPK3 (Table IX in 
the Data Supplement). In addition, 2 perfect proxies were 
associated with increased expression of CSPG4P11 in tis-
sue from the tibial nerve (P=1.4×10−6 and 2.2×10−6) and 
rs11073730, along with 14 proxies in strong LD (r2=0.8–1) 
was associated with increased expression of WDR73 in the 
muscular layer of the esophagus (P=3.3×10−7 to 1.4×10−9). 
We identified another locus in an intergenic region on chro-
mosome 4, with the most significant variant (rs11099412) 
≈700 kb downstream of the closest gene PCDH18. Finally, a 
locus was identified on chromosome 6, ≈150 kb downstream 
of the gene C6orf195. A strong proxy (r2=0.9) for the most 
significant variant was previously associated with orthostatic 
hypotension.26
In the African American population, one locus was 
identified on chromosome 11. The most significant variant 
(rs10832139) was located 44 kb upstream of the closest gene, 
SPON1.
Genetic Loci Associated With Heart Rate, P-Wave Duration, 
and P-Wave Terminal Force
On chromosome 14, we identified a locus with the most sig-
nificant variant located intronic to MYH6. Rs445754 was 
in moderate LD with the most significant variant from the 
P-wave duration analysis in the present study (rs452036; 
CEU r2=0.7) and the most significant variant from the first 
GWAS on heart rate (rs365990; CEU r2=0.6).16 The variant 
rs365990 has been replicated in 3 subsequent GWAS of heart 
rate.16,24,25
Variance Explained by the Genetic Loci Associated 
With P-Wave Duration and P-Wave Terminal Force
The most significant SNPs associated with P-wave duration 
explained 0.08% to 0.83% of the total variance (Tables IV and 
V in the Data Supplement), while the variants associated with 
P-wave terminal force explained 0.09% to 0.47% of the total 
variance (Tables X and XI in the Data Supplement).
P-Wave Duration and P-Wave Terminal Force Are 
Genetically Associated
After LD clumping (r2>0.5), 199 significant SNPs remained 
from the P-wave duration analysis and 85 significant SNPs 
remained from the P-wave terminal force analysis, which 
were included in the respective GRS. The P-wave terminal 
force GRS was associated with measured P-wave duration 
(β=0.00095; SE=0.00014; P=2.5×10−11), and the P-wave 
duration GRS was associated with measured P-wave termi-
nal force (β=8.33; SE=1.64; P=3.6×10−7). Using lower r2 
thresholds for the LD clumping produced similar results, with 
even lower P values (Results in the Data Supplement). One 
unit increase in the genetically determined P-wave terminal 
force was associated with a 0.00095 ms increase in P-wave 
duration, whereas 1 U increase in the genetically determined 
P-wave duration was associated with an 8.33 µV x ms increase 
in P-wave terminal force. The estimated percentage of total 
variance of the measured P-wave terminal force explained by 
the P-wave duration GRS is 0.07%, and conversely, the esti-
mated fraction of the total variance of the measured P-wave 
duration explained by the P-wave terminal force GRS is 0.1%.
Discussion
In the current work, we sought to characterize the genetic basis 
of the P wave and to integrate our findings with prior associa-
tion studies of electrocardiographic traits quantifying atrial con-
duction. Our results reveal both unique and overlapping genetic 
loci for the different phases of atrial conduction (Figure 4). 
As expected, the phenotypic variance explained by the causal 
SNP from each genetic locus associated with P-wave duration 
and P-wave terminal force was small (0.08%–0.83%). Similar 
estimates have been reported for common variants associated 
with other continuous traits, such as human height and BMI, 
and reflect the often highly polygenic nature of common traits, 
which are, thus, explained by a large number of variants with 
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small effect sizes. The larger percentage of variance explained 
by the variants identified in the African American ancestry 
groups is caused by the large effect sizes of these SNPs.
In Discussion in the Data Supplement, we have provided a 
detailed description of the loci that are unique to either P-wave 
duration or P-wave terminal force, and we have discussed the 
broad contribution of the sodium channels, caveolin, and 
TBX5 to atrial conduction.
Interrelationship Between P-Wave Duration and 
P-Wave Terminal Force
P-wave duration and P-wave terminal force are both endophe-
notypes for AF; however, they represent different aspects of 
atrial conduction. P-wave duration reflects the depolarization of 
both right and left atrium, while P-wave terminal force, which 
is calculated from the last half portion of the P-wave, more 
specifically represents left atrial activation. Soliman et al4 have 
shown that the mutual PWI correlations are weak to moderate 
in a study of more than 15 000 individuals. In particular, P-wave 
duration and P-wave terminal force displayed the weakest cor-
relation (Pearson’s R=0.08–0.29). In this study, we found that 
the genetically determined P-wave duration is highly associated 
with the measured P-wave terminal force and vice versa but that 
the percentage of explained variance between the 2 PWI was 
small. Thus, we had expected to identify genetic loci uniquely 
associated with either right or left atrial activation, in addition 
to some overlap of genetic variants associated with both phe-
notypes in the present study. We did discover one genetic locus 
associated with both P-wave duration and P-wave terminal 
force, encompassing the gene MYH6. The 14q11 locus includes 
MYH6, the gene encoding myosin heavy chain 6 protein, which 
is important in actin and calmodulin binding in the sarcomere 
of striated muscles. The most significant variant at this locus, 
rs452036, and its proxy rs365990 (CEU r2=0.96) have been 
associated with heart rate in multiple GWAS16,23,24 and most 
likely represent the same locus. MYH6 has been implicated in 
congenital heart defects,27 dilated and hypertrophic cardiomy-
opathy,28,29 AF,30 atrial septal defects,31,32 and sick sinus syn-
drome.33 All of these conditions may affect inter- or intra-atrial 
conduction and modify P-wave duration.
According to reports that P-wave terminal force is a predic-
tor of left atrial enlargement,8 one might have expected to see 
a predominance of structurally related genes associated with 
P-wave terminal force and a preponderance of genes involved 
in electric properties of the atrium associated with P-wave dura-
tion. Indeed, some of the genes identified in the analyses of 
P-wave duration are more likely to produce electric disturbances 
(SCN5A, SCN10A, HCN1, CAV1/CAV2, EPAS1, CAND2, and 
CAMK2D), while a selection of the genes identified in the analy-
ses of P-wave terminal force are more likely to cause structural 
changes (TBX5, ALPK3/NMB, MYH6, and SPON1). However, 
recent studies have reported that P-wave terminal force was not 
associated with left atrial enlargement on echocardiography34 or 
computed tomography volume measurement.35 In a sample of 
275 middle-aged Americans referred to cardiovascular magnetic 
resonance imaging between 2001 and 2004, electrocardiographic 
Figure 3. Manhattan plot of meta-analysis results for genome-wide association of P wave terminal force for European and African Ameri-
can ancestry. A, European ancestry meta-analysis results. B, African American ancestry meta-analysis results. The dashed horizontal lines 
represent the genome-wide significance threshold. Genetic loci that reached genome-wide significance are highlighted in blue.
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P-wave terminal force (negative P terminal force in V1>0.04 s 
x mm) had high specificity (88%) but low sensitivity (37%) and 
positive predictive value (47%) for left atrial enlargement, com-
pared with volumetric assessment of left atrial size.36
Strengths and Limitations
Strengths of our study include the substantial power obtained 
by including >44 000 individuals from established stud-
ies with carefully phenotyped participants. Further, the PWI 
measurements were all measured digitally and calculated 
automatically. Last, because AF is thought to originate pre-
dominantly from the left atrium and pulmonary veins, evalua-
tion of eQTLs in a large sample of left atrial samples provides 
a suitable model for functional interrogation of the genetic 
variants associated with AF in our study.
Our study was also subject to several limitations. First, both 
P-wave duration and P-wave terminal force measurements are less 
reproducible over time than PR interval, P-wave axis, and P-wave 
Figure 4. Integrated view of the anatomic, electric, and genetic architecture of atrial conduction. Top, Heart, anterior 4-chamber view, 
with the different phases of atrial conduction color-coded. Purple, sinoatrial node activity (heart rate); green, P wave duration; red, PR 
segment; blue, PR interval; gray, P wave terminal force; and yellow, overall atrial conduction. Middle, ECG corresponding to the differ-
ent phases of atrial conduction. Bottom, All identified risk genes for heart rate (R-R), PR interval, and P wave indices. For each trait, only 
genes uniquely associated with that trait are listed. Genes associated with multiple electrocardiographic traits are listed under multiple 
atrial conduction traits. Red font, novel loci in the present study; green font, loci identified in both the present study and previous litera-
ture; black font, loci only identified in previous studies. AV indicates atrioventricular; LA, left atrium; LV, left ventricle; PTF, P-wave terminal 
force; RA, right atrium; RV, right ventricle; and SA, sinoatrial.
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area.37 Second, one could consider adjusting the P value for sig-
nificant results for the 2 traits considered (5×10−8/2=2.5×10−8); 
however, the P-wave duration and P-wave terminal force are only 
weakly correlated, and so we used a conventional threshold for 
genome-wide significance of 5×10−8. Third, associations with P 
values in the range of 1×10−8 to 10−10 will require replication in 
independent cohorts. Fourth, although we included individuals 
of both European and African ancestry, our findings may not be 
generalizable to other ancestries. Fifth, the analyses in African 
Americans were underpowered compared with our analyses in 
European-ancestry individuals and require replication as other 
studies become available in the future. Finally, it is important 
to remember that we have identified markers of genetic regions 
involved in the P-wave indices. The genes outlined above are 
the genes closest to the most significant variant in each genetic 
region, yet it remains unclear whether they truly are the effec-
tor genes. Other genes in the same region or even more distantly 
located genes might actually be the causal genes. Future studies 
including targeted mapping of these loci and functional analyses 
of the implicated genes may shed light on the underlying biology.
Conclusion
We report 15 genetic loci associated with P-wave duration and 
P-wave terminal force, 4 of which harbor significant eQTLs in left 
atrial tissue. In the context of the existing knowledge of genetic 
factors for atrial conduction, a genetic architecture is emerging, in 
which specific genetic regions influence different phases of atrial 
conduction. Functional characterization of the novel loci may 
clarify the underlying pathophysiology and aid the discovery of 
targets for new drugs, which may modulate atrial conduction and, 
thus, potentially treat a range of arrhythmia disorders.
Web Resources
The Genotype-Tissue Expression (GTEx) browser, http://
www.gtexportal.org
SNAP proxy search, http://www.broadinstitute.org/mpg/
snap/
Locus zoom, https://statgen.sph.umich.edu/locuszoom/
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CLINICAL PERSPECTIVE
The electrocardiographic P wave is a measure of electric activation of the atria that can be quantified by assessing the P-wave 
duration or P-wave terminal force. Because measures of atrial activation have been associated with left atrial enlargement 
and atrial fibrillation, we sought to determine the genetic basis of P-wave duration and P-wave terminal force. We identified 
6 new genetic loci that contribute to the maximum P-wave duration and 6 genetic loci that contribute to the P-wave terminal 
force. When integrating our results with prior work, we have identified a genetic architecture of the P wave in which some 
genetic loci are uniquely associated with distinct electrocardiographic parameters and others are more broadly associated 
with atrial conduction. Further studies evaluating the function of the genetic loci linked to atrial conduction may help eluci-
date the biology underlying atrial conduction, as well as provide new targets for antiarrhythmic drugs.
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